EMCURE Emcure Pharmaceuticals Q2 FY26 results (Jul–Sep 2025) and concall
Emcure Pharmaceuticals delivered a strong Q2 FY26, driven by sustained momentum across all business segments, leading to double-digit revenue and profit growth. Strategic initiatives like the Novo Nordisk partnership for semaglutide and the full consolidation of Zuventus are expected to further bolster future growth and market positioning. The company remains on track with its annual guidance for margin improvement and aims for debt reduction in the coming 18-24 months.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 13.4%, net profit up 24.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 2,002 | 1,963 | 2,116 | 2,101 | 2,270 +13% |
| EBITDA | 381 | 355 | 402 | 417 | 475 +25% |
| Net profit | 202 | 156 | 197 | 215 | 251 +24% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
